Merck to broaden use of Certara’s Pinnacle 21 platform, adding metadata repository and standards workflow tools

Certara, Inc., a global leader in model-informed drug development, today announced an expanded collaboration with Merck (known as MSD outside the US and Canada), extending the use of its Pinnacle 21 enterprise software platform across Merck’s clinical data operations.

Building on an existing relationship focused on regulatory submissions, the new agreement will see Merck adopt Pinnacle 21’s metadata repository and workflow management tools to further streamline its data standards processes.

As the volume and complexity of clinical trial data continues to rise — with Phase 3 trials now averaging 3.6 million datapoints, a threefold increase over the past decade¹ — standardized, analysis-ready data is critical for timely, high-quality decision-making.

William Feehery,CEO at Certara, said: “We’re pleased to strengthen our collaboration with Merck and support their leadership in research data management. Together, we’re working to accelerate high-quality data delivery across the development cycle.”

The Pinnacle 21 platform is designed to support digital trial strategies at scale, addressing industry-wide challenges around data standardisation, regulatory compliance, and process efficiency.